<DOC>
	<DOC>NCT02910817</DOC>
	<brief_summary>a quasi-experimental study to investigate whether metformin co-treatment would improve IVF outcomes in overweight and obese women with PCOS.</brief_summary>
	<brief_title>Impact of Metformin on In Vitro Fertilization Outcomes in Overweight and Obese PCOS Women</brief_title>
	<detailed_description>This was non randomized prospective controlled "metformin-free group" study that took place in a University IVF Center. The study included fifty-one overweight and obese women (BMI&gt;25) with PCOS underwent their first fresh autologous IVF-embryo transfer cycle and agreed to take metformin during their IVF cycles "Metformin-treated group". A cross matched cohort of fifty-one cross matched PCOS women who did not agree to take the study medication was allocated to the control group "Metformin-free group". The metformin-treated group received metformin (1000 mg per day) with the start of controlled ovarian stimulation (COH) until the day of the pregnancy check. The primary outcome measures were the total number of retrieved oocytes and the live birth rate.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>The inclusion criteria restricted the patients to 39 years old with basal FSH &lt; 10 IU/ml and normal TSH and prolacin. Exclusion criteria were diabetes mellitus (excluded by GTT), renal or liver disease, associated male factor, documented tubal factor or pelvic adhesions, elevated 17 alfa hydroxyprogesterone level and FSH â‰¥10 IU/ml. We also excluded the women who started program or medications to reduce their weight and those who their partner has abnormal semen parameters according to the world health organization parameters (WHO, 2010)</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>